Skip to Content

PTEN Mutation Analysis

Indication

To detect and type mutations in the PTEN tumor suppressor gene for diagnosis of Cowden disease and Bannayan-Riley-Rucvalcaba syndrome and for prognosis and therapy selection in range of cancer types, particularly endometrial carcinoma, glioblastoma multiforme, melanoma, and prostatic carcinoma.

Methodology

This assay is part of the Next Gen Sequencing panel for solid tumors.

Test Parameters

Next generation sequencing-based analysis is performed to detect point mutations in mutational hotspots in the PTEN gene. The codons tested include, 6, 68, 173, 171, 214, 242, 248, 267, 290, 317, 318, 319, 321, 323, 335.

Turnaround Time

10 days

Sample Requirements

5ug purified DNA or 4-10 unstained tissue sections on glass slides along with 1 H&E-stained section.

81479


© 2014 The University of Texas MD Anderson Cancer Center